Linagliptin, Color : White, Formula : C25H26N8O2

Niksan Pharmaceutical is one of the biggest manufacturer, supplier, exporter and trader of the LINAGLIPTINfinished formulations moreover LINAGLIPTIN API. Niksan Pharmaceutical is the huge manufacturer, exporter and supplier of LINAGLIPTIN API and formulation situated in Ankleshwar, Gujarat, India.

Niksan Pharmaceutical is the suppliers, manufacturer, exporters and trader of
LINAGLIPTIN inthe domestic level as well as the international market.

Niksan is an Indian based pharmaceutical company so it also supplies and manufactures the LINAGLIPTIN to all Indian states like Gujarat, Maharashtra, Punjab, Delhi, Tamilnadu, Goa, Uttar Pradesh, Karnataka, Jammu & Kashmir, West Bengal, Assam, Rajasthan, Hyderabad, Karnataka, Kerala, Madhya Pradesh, Manipur, Meghalaya, Mizoram, Nagaland, Orissa, Punjab and Haryana.  

Niksan Pharmaceutical and Niksan group companies are exporters, suppliers and manufacturers of the API and also LINAGLIPTIN formulations in many countries for many years. Niksan pharmaceutical currently exports LINAGLIPTIN API and Formulation to countries like New Zealand, Jordan, Belgium, United Kingdom, Australia, Italy, Ireland, Hong Kong, Morocco, Portugal, France, South Africa, Philippines, Malaysia, Singapore, Israel, Greece, Saudi Arabia, Egypt, Taiwan, Netherlands, South Korea, Switzerland, Algeria, Pakistan, Canada, Vietnam, United States, Germany, Brazil and many other countries.

LINAGLIPTINbelongs to a class of medications called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors). It is used in the management of Type 2 Diabetes Mellitus to improve glycemic control in combination with diet and exercise.

SYNONYSMS:BI 1356, Trajenta

IUPAC NAME: 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(5-methyl-1H-pyrazol-4-yl)-8-(propylamino)-1,2,4-triazolo[4,3-a]piperazine

CAS NO:668270-12-0

FORMULA:C25H28N8

MOLECULAR MASS:  472.54  g/mol

STORAGE CONDITIONS:Store in a tightly sealed container. Keep in a cool and dry place away from light and moisture. Do not store in the bathroom. Keep away from children and pets.

HOW TO USE:Take this medication by mouth once daily with or without food. Use it regularly to get the most benefit from it. Continue to follow your doctor’s diet and exercise recommendations.

HOW LINAGLIPTIN WORKS:Linagliptin works by inhibiting the DPP-4 enzyme, which results in increased levels of incretin hormones. These hormones increase insulin release and decrease glucagon levels in the circulation in a glucose-dependent manner, thereby lowering blood glucose levels.

PHARMACOKINETICS OF LINAGLIPTIN:

Absorption: Peak plasma concentration is reached within 1.5 hours.

Bioavailability: Approximately 30%.

Protein Binding: About 75-99%.

Metabolism: Minimal hepatic metabolism.

Elimination: Mostly excreted unchanged via feces (~80%).

Half-life: Terminal half-life is over 100 hours.

SIDE EFFECTS OF LINAGLIPTIN:Common side effects include upper respiratory tract infection, stuffy or runny nose, sore throat, cough, and joint pain. Rare but serious side effects include pancreatitis, allergic reactions, and hypoglycemia (especially if used with other antidiabetic agents).

PRECAUTIONS: Inform your doctor if you are allergic to Linagliptin or any other medications. Caution is advised if you have a history of pancreatitis, kidney or liver problems, or heart failure. Monitor blood glucose levels regularly. Not recommended during pregnancy or breastfeeding unless clearly needed.

CDSCO APPROVAL:

Linagliptin 5mg Tablet – Approved on 07.07.2014

Linagliptin 5mg + Metformin 500/1000mg Tablets – 20.03.2015

Linagliptin 5mg + Empagliflozin 10/25mg Tablets – 06.11.2016

FORMULATIONS AVAILABLE IN MARKET:

Linagliptin 5 MG tablets

Linagliptin + Metformin tablets

Linagliptin + Empagliflozin tablets

Note: Product protected by valid patents are not offered for sale in countries where such patents are still valid and its liability is at Buyers Risk